drugset / Trial / NCT04701021
TENDU Vaccine in Patients With Relapse After Primary Radical Prostatectomy
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I, dose selection study of safety and effect of different doses of TENDU vaccine, a therapeutic peptide conjugate vaccine, in patients with relapse after primary radical prostatectomy.
Timeline
- Start
- 2021-02-17
- Primary completion
- 2023-08-16
- Completion
- 2023-08-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TENDU | Vaccine | 40 ug | Subcutaneous |
| Subject | TENDU | Vaccine | 400 ug | Subcutaneous |
| Subject | TENDU | Vaccine | 960 ug | Subcutaneous |